Nordic Group Appoints Oculoplastic Surgeon, John P. Fezza, MD, to its Medical Advisory Board

Nordic Pharma announced that oculoplastic surgeon John P. Fezza, MD, will serve on its US Medical Advisory Board (MAB), which includes Eric Donnenfeld, MD (New York), Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).

Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for dry eye disease, Lacrifill Canalicular Gel. The FDA-cleared, cross-linked hyaluronic acid derivative Lacrifill is intended to temporarily block tear drainage by the occlusion of the canalicular system.

“The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair. “John will bring his unique perspective and understanding of the lacrimal drainage system to Lacrifill's novel treatment of dry eye disease.”

“I am thrilled to join this incredible Medical Advisory Board comprised of some of the most esteemed leaders in eye care,” said Dr. Fezza. “They share a common vision of improving patient care, and understand the importance of treating dry eye disease. As the inventor of Lacrifill Canalicular Gel, I believe we are launching a novel product that will change our approach to treating dry eyes.”

Nordic Pharma’s U.S. Medical Advisory Board brings together leading eye care providers from across the country, including ophthalmologists and optometrists in private practice and affiliated with major health systems. “John’s addition to our U.S. Medical Advisory Board provides historical and unique insights to this stellar group of optometry and ophthalmology leaders that will help set us up for a successful launch of

Lacrifill Canalicular Gel is set to launch later this year under the Nordic Pharma brand.

Members of the Lacrifill team will be attending Vision Expo East 2024 to share the benefits of Lacrifill Canalicular Gel with optometrists and to discuss select pre-order opportunities.